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SHORT REPORT Open Access
Defective pro-IL-1β responses in macrophages
from aged mice
Alejandro Ramirez, Vijay Rathinam, Katherine A Fitzgerald, Douglas T Golenbock and Anuja Mathew*
Abstract
Background: Cytokines regulated by the inflammasome pathway have been extensively implicated in various
age-related immune pathologies. We set out to elucidate the contribution of the nod-like receptor protein 3
(NLRP3) inflammasome pathway to the previously described deficiencies in IL-1β production by macrophages from
aged mice. We examined the production of pro-IL-1β and its conversion into IL-1β as two separate steps and
compared these cytokine responses in bone marrow derived macrophages from young (6–8 weeks) and aged
(18–24 months) C57BL/6 mice.
Findings: Relative to macrophages from young mice, macrophages from aged mice produced less pro-IL-1β after
TLR4 stimulation with LPS. However upon activation of the NLRP3 inflammasome with ATP, macrophages from
young and aged mice were able to efficiently convert and secrete intracellular pro-cytokines as functional cytokines.
Conclusions: Lower levels of IL-1β production are a result of slower and lower overall production of pro-IL-1β in
macrophages from aged mice.
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Findings
Immunosenescence has been associated with altered
levels of pro and anti-inflammatory cytokines such as
IL-1β, TNF-α, IL-6, IL-10, TGF-β and Prostaglandin E2
in the blood of aged individuals [1-3]. These aberrant
cytokine responses are thought to contribute to the in-
ability of the elderly to mount appropriate immune
responses to pathogens, vaccines and self antigen [4].
Macrophages from aged mice have a lower production
of cytokines when activated with IFN-γ or LPS [5] and
decreased TNF-α and IL-6 production when infected
with Porphyromonas gingivalis [6] compared to macro-
phages from young mice. Furthermore bone marrow
derived macrophages (BMM) from aged mice secrete
less IL-1β compared to BMM from young mice when
stimulated with LPS for 6 hours [7]. IL-1β and IL-18
have been associated with a wide variety of age asso-
ciated diseases including rheumatoid arthritis, multiple
sclerosis, atherosclerosis, gout, immunosenescence and
greater susceptibility to infectious disease [8-12] thus
highlighting the importance of inflammasome regulated
cytokines in the aging process [13,14].
The inflammasome is a multiprotein complex that reg-
ulates IL-1β and IL-18 secretion by signal recognition
via TLRs in combination with NLR or PYHN sensor
proteins [15,16]. There are two distinct regulatory steps
in the production of active IL-1β. The first step is the
production of the biologically inert precursor pro-IL-1β
in response to stimulation by a TLR ligand. The second
step is the processing of the immature form of the cyto-
kine into its active form by the inflammasome complex.
The NLRs are a large family of cytosolic sensors and the
best studied one is NLRP3 which forms part of a family
of inflammasomes important in detecting many patho-
gens including influenza virus, Candida albicans, Sac-
charomyces cerevisiae and Staphylococcus aureus [17].
While previous groups have shown that cells from aged
mice produce lower levels of IL-1β, it is unclear whether
these defects lie primarily at the priming stage and/or
maturation stage of these critical cytokines. The success
of immunomodulatory intervention to enhance or
dampen aberrant inflammatory cytokine responses in
aged individuals will likely depend on identifying and* Correspondence: anuja.mathew@umassmed.edu
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targeting key molecules in inflammatory pathways in-
cluding the inflammasome.
We investigated the contribution of the NLRP3
inflammasome pathway to the previously reported low
levels of IL-1β in the aged. Bone marrow cells from
young (6–8 weeks) and sex matched aged (18–
24 months) mice were differentiated into macrophages
using L929 cell conditioned medium containing M-CSF.
The resulting cell population expressed F4/80 and
CD11b markers with correct myeloid characteristics
assessed by flow cytometry (data not shown). BMM
from young and aged mice were plated on 24-well plates
at a density of 1x106 cells/ml and left to settle overnight
at 37 °C. BMM were first primed with LPS (200 ng/ml),
a TLR4 agonist, for 3 hours to elicit the production of
pro-IL-1β. Following priming, cells were stimulated with
the NLRP3 agonist ATP (5 mM) for 1 hour in order to
activate assembly of the inflammasome, resulting in pro-
caspase activation and ultimately cleavage and extracel-
lular release of IL-1β. Our data indicated that BMM
derived from young mice produced significantly more
IL-1β in the supernatant as detected by ELISA compared
to BMM from aged mice (Figure 1A). Western blots fur-
ther confirmed a significant increase in levels of fully
processed and functional 17 kDa fragment of IL-1β in
BMM from young compared to BMM from aged mice.
However activation of the NLRP3 inflammasome path-
way measured by the presence of active Caspase-1 sub-
unit p20, or the p35 pro-Caspase-1 intermediates were
similar in BMM from both young and aged (Figure 1C).
The data suggested that defects in BMM from aged mice
were likely associated with inadequate production of the
proactive cytokine, pro-IL-1β. We next assessed basal
levels of pro-IL-1β by using flow cytometry with an
antibody which only binds to the pro-from of IL-1β
(NJTEN3). We found similar levels of pro-IL-1β mea-
sured as geometric mean fluorescence intensity (GMFI)
in unstimulated BMM from both young and aged mice
(Figure 2A/B). However, after priming with LPS for
3 hours, BMM from young mice had greater intracellu-
lar production levels of pro-IL-1β (Figure 2A/B). Follow-
ing NLRP3 activation with ATP, BMM from both young
and aged were able to effectively convert most of the
pro-IL-1β content, seen as a reduction in intracellular
pro-IL-1β (Figure 2B) and an increase in extracellular
levels of active IL-1β (Figure 2C). Our data thus far sug-
gested that the defect in IL-1β production by BMM from
older mice occurred at the priming stage. We performed
a kinetic analysis of pro-IL-1β production to determine
whether the observed differences in BMM from young
versus aged were reflective of differences in the kinetics
of production or an overall decreased production of pro-
IL-1β in BMM from aged mice. Our data indicate
decreased pro-IL-1β secretion at early time points (3
and 6 hrs) following LPS priming in BMM from aged
(Figure 3A). In BMM from young, pro-IL-1β levels
decreased after the 6 hr time point, while levels of pro-
IL-1β increased in cells from aged mice up to 24 hrs. To
confirm that inflammasome assembly and caspase-1 ac-
tivity in BMM from aged were similar to BMM from
young we activated the NLRP3 pathway at 3 hrs when
there was a significantly lower pro-IL-1β levels in BMM
from aged mice or 24 hrs where there was a similar
intracellular content of pro-IL-1β in BMM from both
young and aged after LPS priming. When the NLRP3
complex was activated by ATP at the 24 hr time point,
we detected higher levels of IL-1β (Figure 3C) and IL-18
(Figure 3E) in the supernatant of BMM from aged.
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Figure 1 Macrophages from aged mice produce less functional IL-1β but have similar levels of active Caspase-1. BMM were primed with
LPS (200 ng/ml) for 3 hours and stimulated with ATP (5 mM) for one hour. IL-1β levels in the supernatant of stimulated BMM determined by
ELISA (A). Data shown are the mean values from triplicate wells +/− SEM. Representative data of at least 3 experiments each performed in
triplicate. Immunoblot analysis of the fully processed 17 kDa fragment of IL-1β in supernatants of BMM from young and aged mice stimulated
with LPS + ATP (B). Immunoblot of active Caspase-1 (p20) subunit and pro Caspase 1 intermediate (p35) in the supernatants from stimulated
young and aged BMM (C).
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Figure 2 Efficient processing of pro-IL-1β in BMM from aged mice. BMM were primed with LPS (200 ng/ml) for 3 hours or primed and
stimulated with ATP (5 mM) for one hour (LPS + ATP). Intracellular production of pro-IL-1β as measured by GMFI was assessed in control, LPS and
LPS + ATP treated BMM from young and aged mice using the NJTEN3 Ab at 0.05 μg per 106 cells (eBiosciences) (A/B). Controls were incubated
with cell culture medium. ELISA of extracellular active IL-1β in supernatants of control, LPS and LPS + ATP treated BMM from young and aged
mice (C). Data shown are mean values from triplicate wells +/− SEM. Representative data of at least 3 experiments each performed in triplicate.
(* = P <0.05, ** = P < 0.01 Mann-Whitney Test).
G
M
FI
Young
Aged
Hours with LPS
IL-1β 3Hr IL-1β 24Hr
LPS + ATP         LPS            Control
8000
4000
2000
6000
0        3        6        9       12      15       18     21      24      27      30
IL-18 3Hr IL-18 24Hr
LPS + ATP         LPS            Control LPS + ATP         LPS            Control
LPS + ATP         LPS            Control
1000
500
1500
500
1000
25
20
15
10
5
0
30
20
10
0
0
0
Young
Aged
Young
AgedPro-IL-1β
A B C
D E
pg
/m
l
pg
/m
l
pg
/m
l
pg
/m
l
Figure 3 Age related differences in IL-1β secretion correlate with intracellular pro-IL-1β content. Time course of intracellular pro-IL-1β
production levels in LPS (200 ng/ml) stimulated BMM from young and aged mice using flow cytometry (A). ELISA of IL-1β (B and C) and IL-18
(D and E) levels in supernatants of young and aged BMM stimulated with LPS (200 ng/ml) for 3 and 24 hours respectively and ATP (5 mM) for
1 hour. Controls were incubated with cell culture medium. Data shown are the mean values from triplicate wells +/− SEM. Representative data of
at least 3 experiments each performed in triplicate.
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These results suggest that BMM from aged mice do not
have a defect in NLRP3 inflammasome assembly or
caspase-1 activity.
Our results taken together indicate that BMM from
aged mice may have a significant defect downstream of
TLR4 signaling which leads to a reduced output of
inflammasome associated cytokines IL-1β and IL-18.
BMM from aged mice have a functional IL-1β response
but with different kinetics of production as well as a
lower overall level of production compared to BMM
from young mice. These findings are consistent with the
research from other groups which have shown lower se-
cretion of TLR4 dependent cytokines in macrophages
from aged mice, which are not dependent upon inflam-
masome processing, such as TNF-α or IL-6 [18].
Stout-Delgado et al. have recently shown that nigeri-
cin, an NLRP3 inducer used in favor of TLR agonists,
potentiated IL-1β responses to influenza A virus in aged
mice resulting in improved survival and better outcome
of infection [19]. Our data indicate that this strategy
takes advantage of the fully functional inflammasome re-
sponse to strong NLRP3 agonists like nigericin or ATP
by myeloid cells in aged mice. Our study has implica-
tions to understanding immunomodulatory strategies
that are needed to boost waning immunity in the elderly
[20]. Successful application of these strategies will re-
quire controlled stimulation of protective immune
responses without exacerbating the release of potentially
harmful proinflammatory cytokines.
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